ea0072p3 | (1) | UKINETS2020
Chen Luohai
, Gnanasegaran Gopinath
, Mandair Dalvinder
, Toumpanakis Christos
, Caplin Martyn
, Navalkisoor Shaunak
Background: 177Lu-DOTATATE is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few circulating biomarkers are available to predict progression-free survival (PFS) of patients received 177Lu-DOTATATE.Materials and methods: Clinicopathological data and data of baseline circulating biomarkers including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), e...